Search for: "Ranbaxy Inc. " Results 101 - 120 of 142
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
9 Mar 2011, 3:00 am by Marie Louise
Allergan, Inc (Chicago IP Litigation Blog) Synagis (Palivizumab) – US: PDL BioPharma settles Medimmune Synagis litigation for $93M (Patent Docs) TriCor (Fenofibrate) – US: Abbott and Elan end TriCor suit with Ranbaxy (Patent Docs) Valsartan – Norway: Oslo District Court holds Actavis’ Valsartan/HCTZ product infringes Novartis’ patent covering synthesis route for Valsartan; deals inter alia with scope of Valsartan SPC (The SPC Blog) [read post]
1 Apr 2014, 9:50 pm by Zachary Ewing
Earlier in 2013, generic-drug-maker Ranbaxy agreed to pay $500 million in fines and settlement costs after the company pled guilty to federal drug safety violations. [read post]
14 Dec 2007, 1:00 am
Gore & Associates Inc. held to have willfully infringed rival C.R. [read post]
25 Jan 2019, 12:08 pm by Katherine Kiziah
MDL No. 2879 – In Re: Marriott International, Inc., Customer Data Security Breach Litigation. [read post]
25 Jan 2019, 12:08 pm by Katherine Kiziah
MDL No. 2879 – In Re: Marriott International, Inc., Customer Data Security Breach Litigation. [read post]
22 Feb 2008, 6:00 pm
Signature Financial Group, Inc., and AT&T Corp. v. [read post]
5 Aug 2009, 5:35 am
. - Patent Docs) US: America’s Affordable Health Choices Act : House Energy & Commerce Committee OKs 12-year data exclusivity for biotech drugs (Patent Baristas) (Patent Docs) (FDA Law Blog) (PatentlyBIOtech) (GenericsWeb) US: Patents and data exclusivity: It ain’t necessarily so (Patent Docs) US: Teva fights for biotech generics (GenericsWeb) US bill considers access to Canadian pharmaceuticals (Pharmacapsules@Gowlings) US: Bilski and biotechnology – an update… [read post]
28 Apr 2008, 11:00 am
: (Patent Docs), US: Supreme Court declines to hear final Nucleonics’ appeal in gene-silencing patent dispute with Benitec Australia: (IP Law360), (Therapeutics Daily), US: 505(b)(2) drug approvals rock - Interaction of patents and exclusivity of drugs approved by FDA under section 505(b)(2): (Patent Baristas), US: StemCells’ patents survive reexam – StemCells and Neuralstem differ on extent of changes: (Patent Docs), US: StemCells announces issuance of… [read post]
3 Mar 2010, 5:05 am
(IP Think Tank) US: Reverse payments in generic drug settlements (Part II - Patent Docs) (Part III - Patent Docs) (Part IV - Patent Docs) US: Inability of patent examiner and Board to correctly read prior art reference necessitates intervention by Federal Circuit: In re Chapman (Holman's Biotech IP Blog) (Patent Docs) US: Patent infringement suit between NexMed and Beta Technologies stayed following determination that plaintiff NexMed may not own one of the patents-in-suit related to method of… [read post]
3 Mar 2010, 5:05 am
(IP Think Tank) US: Reverse payments in generic drug settlements (Part II - Patent Docs) (Part III - Patent Docs) (Part IV - Patent Docs) US: Inability of patent examiner and Board to correctly read prior art reference necessitates intervention by Federal Circuit: In re Chapman (Holman's Biotech IP Blog) (Patent Docs) US: Patent infringement suit between NexMed and Beta Technologies stayed following determination that plaintiff NexMed may not own one of the patents-in-suit related to method of… [read post]
24 Feb 2010, 2:11 am
(IP Watch) Exploring a new angle in the TRIPS and drug patents debate (Spicy IP) EPO Enlarged Board of Appeal rules on patenting a method of treatment by surgery: G1/07 (IPKat) (EPLAW) (Patent Baristas) EPO Enlarged Board of Appeal decides on dosage regime – Swiss-type claims no longer available: G 2/08 – Dosage Regime/Abbot Respiratory (EPLAW) (Managing Intellectual Property) (IPKat) (Patent Baristas) India: Victory for access to medicines as Bayer loses lawsuit in India (GenericsWeb)… [read post]
24 Feb 2010, 2:11 am
(IP Watch) Exploring a new angle in the TRIPS and drug patents debate (Spicy IP) EPO Enlarged Board of Appeal rules on patenting a method of treatment by surgery: G1/07 (IPKat) (EPLAW) (Patent Baristas) EPO Enlarged Board of Appeal decides on dosage regime – Swiss-type claims no longer available: G 2/08 – Dosage Regime/Abbot Respiratory (EPLAW) (Managing Intellectual Property) (IPKat) (Patent Baristas) India: Victory for access to medicines as Bayer loses lawsuit in India (GenericsWeb)… [read post]
22 Mar 2008, 2:00 am
: (IPBiz),US: Two remaining challenged WARF embryonic stem cell patents upheld in ex parte reexamination: (Holman's Biotech IP Blog), Pharma & Biotech - ProductsAricept (Donepezil) – USV wins appeal against USPTO decision: (Spicy IP),Celerex (Celecoxib) – CAFC decision in Celebrex patents dispute between Pfizer and Teva will cut patent term by one and a half years: (Patent Baristas), Inersan – Ranbaxy in-licenses Inersan to CD Pharma to market in… [read post]
29 Feb 2008, 8:00 am
– Teva’s opposition proceedings regarding IL 130424 to Pfizer: (IP Factor), Thailand: Thai chief drug price negotiator removed from post: (GenericsWeb), Thailand: Compulsory licences cannot be revoked: (Generic Pharmaceuticals & IP), (more from Generic Pharmaceuticals & IP), UK: Court of Appeal for England and Wales hands down decision in Boehringer Ingelheim KG and Boehringer Ingelheim Pharma KG v Swingward Limited relating to repackaging and de-branding of… [read post]
18 Apr 2008, 2:00 am
You can separately subscribe to the IP Thinktank Global week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: Ranbaxy and AstraZeneca reach agreement in Esomeprazole patent litigation: (SmartBrief), (IPBiz), (Spicy IP), (Profitability through Simplicity), (IP Law360), (Philip Brooks), (GenericsWeb), Cadbury loses Australian battle over exclusive use of colour purple for chocolate wrapping in its case against Darrell Lea: (Australian Trade Marks… [read post]